Across TCGA pan-cancer cohorts, TXNP5 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated TXNP5 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TXNP5 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TXNP5 expression acts as an unfavorable survival marker, although some lineages such as CESC and COAD show a favorable association.
LIHC, CESC, and PAAD are the cancer types where TXNP5 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.